Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LifeTech Scientific Corporation (LFTSF)
Shenzhen, CN
LifeTech Scientific Corporation, established in 1999 and headquartered in Shenzhen, People's Republic of China, operates as an investment holding company. Its primary focus is the development, manufacturing, and commercialization of state-of-the-art interventional medical devices specifically designed to address cardiovascular and peripheral vascular ailments. The company structures its operations across three distinct segments: Structural Heart Diseases, Peripheral Vascular Diseases, and Cardiac Pacing and Electrophysiology. LifeTech's comprehensive product lineup features a diverse array of critical medical solutions. These include devices such as the LAmbre systems for closing left atrial appendages, a range of CeraFlex, Cera, Heart, and Konara-MF occluders used for ventricular septal defects, and Ankura stent graft systems for both thoracic and abdominal aortic aneurysms. The portfolio also encompasses essential delivery systems like Fustar steerable and SteerEase introducers, Aegisy vena cava filters, Cera vascular plug systems, AcuMark sizing balloons, LawMax dilators, SeQure snare systems, and pacemakers. Beyond its core medical device activities, the corporation engages in biomedical research and development, manufactures and trades hemp-derived materials, provides staff training and internal management services, offers investor information consulting, and delivers various technical and consulting services. LifeTech Scientific boasts a substantial international presence, conducting operations throughout Mainland China, India, other Asian countries, Europe, South America, Africa, and numerous other global markets.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +9.62% | -64.08% | -64.08% | -64.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Devices: +11.2%+2.9% Q2'25: +5.8% (vs Q2'23)
-
EPS growth Medical - Devices: +28.5%-13.9% Q2'25: -74.1% (vs Q2'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+10.4% ★ Q2'25: +54.6% (vs Q2'23)
-
EBIT margin Medical - Devices: +6.2%+15.4% ★ Q2'25: +4.5% (vs Q2'23)
-
ROIC Medical - Devices: +3.3%+7.4% ★ Q2'25: +3.1% (vs Q2'23)
-
Share dilution Medical - Devices: 0.0%-1.2% ★ Q2'25: -3.3% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.02× ★ Q2'25: 0.01× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
311.61M
est: 310.73M (+0.3%)
|
352.85M
est: 328.49M (+7.4%)
|
409.13M
est: 417.84M (-2.1%)
|
556.70M
est: 511.67M (+8.8%)
|
668.88M
est: 716.26M (-6.6%)
|
642.30M
est: 734.39M (-12.5%)
|
925.33M
est: 985.33M (-6.1%)
|
1.10B
est: 1.30B (-15.3%)
|
1.27B
est: 1.31B (-3.6%)
|
1.30B
est: 1.47B (-11.5%)
|
1.38B
est.
|
1.50B
1.50B – 1.50B
+8.9% YoY
|
1.71B
1.71B – 1.71B
+13.6% YoY
|
| EBITDA |
82.34M
est: 108.54M (-24.1%)
|
120.10M
est: 114.75M (+4.7%)
|
211.45M
est: 145.96M (+44.9%)
|
200.03M
est: 178.74M (+11.9%)
|
246.22M
est: 250.21M (-1.6%)
|
314.14M
est: 256.54M (+22.5%)
|
397.59M
est: 344.20M (+15.5%)
|
445.78M
est: 452.47M (-1.5%)
|
253.46M
est: 459.04M (-44.8%)
|
288.88M
est: 514.72M (-43.9%)
|
481.74M
est.
|
524.67M
524.67M – 524.67M
+8.9% YoY
|
596.09M
596.09M – 596.09M
+13.6% YoY
|
| EBIT |
39.65M
est: 88.16M (-55.0%)
|
202.99M
est: 93.20M (+117.8%)
|
194.44M
est: 118.55M (+64.0%)
|
167.47M
est: 145.18M (+15.4%)
|
191.03M
est: 203.23M (-6.0%)
|
268.32M
est: 208.37M (+28.8%)
|
335.54M
est: 279.57M (+20.0%)
|
378.68M
est: 367.51M (+3.0%)
|
176.30M
est: 372.85M (-52.7%)
|
200.89M
est: 418.08M (-52.0%)
|
391.29M
est.
|
426.15M
426.15M – 426.15M
+8.9% YoY
|
484.16M
484.16M – 484.16M
+13.6% YoY
|
| Net Income |
2.36M
est: 88.29M (-97.3%)
|
145.65M
est: 104.89M (+38.9%)
|
163.47M
est: 133.38M (+22.6%)
|
121.08M
est: 146.69M (-17.5%)
|
129.20M
est: 156.51M (-17.4%)
|
216.09M
est: 157.85M (+36.9%)
|
292.47M
est: 352.21M (-17.0%)
|
325.34M
est: 436.34M (-25.4%)
|
263.24M
est: 350.78M (-25.0%)
|
222.39M
est: 307.50M (-27.7%)
|
302.37M
est.
|
345.56M
345.56M – 345.56M
+14.3% YoY
|
475.13M
475.13M – 475.13M
+37.5% YoY
|
| SGA |
121.17M
est: 114.62M (+5.7%)
|
133.20M
est: 121.17M (+9.9%)
|
137.72M
est: 154.13M (-10.6%)
|
224.98M
est: 188.75M (+19.2%)
|
298.86M
est: 264.22M (+13.1%)
|
320.48M
est: 270.90M (+18.3%)
|
291.18M
est: 363.47M (-19.9%)
|
347.70M
est: 477.80M (-27.2%)
|
414.59M
est: 484.75M (-14.5%)
|
504.20M
est: 543.54M (-7.2%)
|
508.72M
est.
|
554.04M
554.04M – 554.04M
+8.9% YoY
|
629.46M
629.46M – 629.46M
+13.6% YoY
|
| EPS |
0.00
est: 0.02 (-95.0%)
|
0.04
est: 0.02 (+50.8%)
|
0.04
est: 0.03 (+25.2%)
|
0.03
est: 0.03 (-16.4%)
|
0.03
est: 0.04 (-12.4%)
|
0.05
est: 0.04 (+39.2%)
|
0.07
est: 0.08 (-15.2%)
|
0.08
est: 0.10 (-22.5%)
|
0.06
est: 0.08 (-26.1%)
|
0.05
est: 0.07 (-27.1%)
|
0.07
est.
|
0.08
0.08 – 0.08
+14.3% YoY
|
0.11
0.11 – 0.11
+37.5% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yuehui Xie | Chairman & Chief Executive Officer | 2M | male |
| Jianxiong Liu | Chief Financial Officer, Executive Vice President, Company Secretary & Executive Director | 2M | male |
| Xingmei Ruan | Chief Compliance Officer | 185.0K | female |
| Liping Wu | Executive Director | 41.8K | female |
| Xiaoling Feng | Executive Director | 41.8K | female |
| Yu Fang | Executive Director | 41.8K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LFTSF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
